56 assets in Skin Squamous Cell Carcinoma

Therapeutic assets addressing Skin Squamous Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
mq719 Skin Squamous Cell Carcinoma	Memorial Sloan Kettering Cancer Center	P1	CC (41)
Recombinant Flt3 Ligand Skin Squamous Cell Carcinoma	University of Southern California	P1	CC (41)
Tocilizumab Skin Squamous Cell Carcinoma	University of Southern California	P1	CC (41)
Tolododekin Alfa Skin Squamous Cell Carcinoma	Ankyra Therapeutics, Inc	P1	CC (41)
Nanrilkefusp Alfa Skin Squamous Cell Carcinoma	SOTIO Biotech AG	P2	D (30)
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE Skin Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	NR ()

Showing 51 to 56 of 56 assets

PreviousPage 2 of 2Next